dc.contributor.author | Jafaar, Mutaz Jamal | |
dc.date.accessioned | 2020-09-26T07:44:25Z | |
dc.date.available | 2020-09-26T07:44:25Z | |
dc.date.issued | 2020-03-12 | |
dc.identifier.uri | http://repository.limu.edu.ly/handle/123456789/1971 | |
dc.description | GDM has been outlined as any degree of glucose intolerance with onset or 1st
recognition throughout pregnancy. though most cases resolve with delivery, the definition
applied whether or not the condition persisted once pregnancy and didn't exclude the
chance that unrecognized glucose intolerance might have antedated or begun
concomitantly with the pregnancy. [1] GDM, the most frequent medical complication of
pregnancy, is associated with several adverse outcomes over the short- and long-term for
both mother and offspring. Standard treatment for GDM consists of insulin injections.
Oral hypoglycemic agents (OHAs), on the other hand, are still the subject of controversy.
Although OHAs are seemingly as efficient as insulin and may provide better quality of
life, congenital malformations and unknown long-term effects are still feared | en_US |
dc.description.abstract | To examine if oral metformin is as effective as insulin in the prevention of hyperglycemia
in pregnancies complicated with gestational diabetes mellitus (GDM). Metformin is a
logical treatment for women with gestational diabetes mellitus, but many studies seems to
be weak to show which the best treatment for GDM due to their small sample that show
no significant differences | en_US |
dc.language.iso | en | en_US |
dc.publisher | faculty of Basic Medical Science - Libyan International Medical University | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.title | Metformin versus Insulin for the Treatment of Gestational Diabetes Mellitus | en_US |
dc.type | Other | en_US |